Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).Alfred L. Garfall, Ajai Chari, Homer Adams et al.|Journal of Clinical Oncology|2020Cited by 42
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Yusri Elsayed, Shun Xin Wang Lin et al.|Targeted Oncology|2022Cited by 21
Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma PatientsSuzette Girgis, Amarnath Sharma, Shun Xin Wang Lin et al.|Blood|2020Cited by 2
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Yusri Elsayed, Shun Xin Wang Lin et al.|Targeted Oncology|2022Cited by 1